Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9538
Name multiple myeloma
Definition A myeloid neoplasm that is located_in the plasma cells in bone marrow.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 over exp Vofatamab multiple myeloma sensitive detail...
FGFR3 Y373C FGFR3 over exp AZ8010 multiple myeloma sensitive detail...
FGFR3 K650E FGFR3 over exp HRAS K117E PD173074 multiple myeloma sensitive detail...
FGFR3 Y373C FGFR3 over exp PD173074 multiple myeloma sensitive detail...
FGFR3 G384D FGFR3 over exp PD173074 multiple myeloma decreased response detail...
FGFR3 G384D FGFR3 over exp AZD4547 multiple myeloma decreased response detail...
FGFR3 G384D FGFR3 over exp AZ8010 multiple myeloma decreased response detail...
NRAS mutant Trametinib multiple myeloma sensitive detail...
BRAF mutant Trametinib multiple myeloma sensitive detail...
FGFR3 Y373C E7090 multiple myeloma sensitive detail...
TP53 wild-type KRT-232 multiple myeloma predicted - sensitive detail...
FGFR3 rearrange FGFR3 K650E Futibatinib multiple myeloma predicted - sensitive detail...
FGFR3 rearrange FGFR3 Y373C Futibatinib multiple myeloma sensitive detail...
FGFR3 rearrange FGFR3 F384L Futibatinib multiple myeloma no benefit detail...
FGFR3 rearrange NRAS act mut Futibatinib multiple myeloma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00734877 Phase III Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide Bortezomib + Dexamethasone + Melphalan + Thalidomide UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma Active, not recruiting USA 0
NCT00881920 Phase I CAR.k.28 cells Cyclophosphamide + Fludarabine Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) Recruiting USA 0
NCT00903968 Phase Ib/II Bortezomib + Plerixafor Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Completed USA 0
NCT00918333 Phase Ib/II Everolimus + Panobinostat Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Completed USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting USA 0
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting USA 16
NCT01146834 Phase III Bortezomib + Filgrastim Bortezomib + Cyclophosphamide + Filgrastim Bortezomib + Cyclophosphamide Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma Completed USA 0
NCT01163357 Phase I Sirolimus Bortezomib + Fludarabine + Melphalan Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma Active, not recruiting USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA 3
NCT01177683 Phase Ib/II Bendamustine + Bortezomib + Pegylated liposomal-doxorubicin Filgrastim Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Terminated USA 0
NCT01208662 Phase III Bortezomib + Dexamethasone + Lenalidomide Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106) Active, not recruiting USA 0
NCT01239368 Phase I Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma Terminated USA 0
NCT01241708 Phase III Bortezomib Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)) Active, not recruiting USA 0
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01287546 Phase I Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab A Study of LY2875358 in Participants With Advanced Cancer Completed USA 0
NCT01301807 Phase I Carfilzomib + Panobinostat Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM) Active, not recruiting USA 0
NCT01313897 Phase II Bortezomib UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35) Completed USA 0
NCT01323751 Phase Ib/II Bortezomib + Dexamethasone Ricolinostat Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Completed USA 0
NCT01326702 Phase Ib/II Veliparib Rituximab Bendamustine Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed USA 0
NCT01345019 Phase III Denosumab Zoledronic acid Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma Completed USA | CAN 27
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Completed USA 3
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting USA 4
NCT01428492 Phase I Afuresertib Bortezomib Dexamethasone Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma Completed USA | CAN 3
NCT01440582 Phase I Bortezomib + Dexamethasone + Lenalidomide + Panobinostat Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients Completed USA 0
NCT01453088 Phase II Melphalan Bortezomib Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older Active, not recruiting USA 0
NCT01453101 Phase II Fludarabine + Melphalan Bortezomib Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Completed USA 0
NCT01456689 Phase I Midazolam LGH447 A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma Completed USA 3
NCT01470131 Phase III Masitinib Bortezomib + Dexamethasone A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma Terminated USA 1
NCT01522872 Phase Ib/II Evofosfamide Bortezomib Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma Unknown status USA 0
NCT01524978 Phase II Vemurafenib Cetuximab A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers Completed USA 5
NCT01526096 Phase I Basiliximab Filgrastim Plerixafor Melphalan Stem Cell Transplantation for Patients With Multiple Myeloma Active, not recruiting USA 0
NCT01547806 Phase II Filgrastim Plerixafor Collection of Transplant Stem Cells for Plasma Cell Myeloma Completed USA 0
NCT01582295 Phase I Cabozantinib XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease Completed USA 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA 6
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Active, not recruiting USA 5
NCT01609816 Phase Ib/II Dasatinib Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant Terminated USA 0
NCT01668719 Phase Ib/II Elotuzumab Bortezomib + Dexamethasone + Lenalidomide S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma Active, not recruiting USA 0
NCT01672736 Phase Ib/II Bortezomib + Dexamethasone + Linsitinib A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma Terminated USA | CAN 0
NCT01689987 Phase I Cyclophosphamide + Dexamethasone + Hydroxychloroquine + Sirolimus Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed USA 0
NCT01695330 Phase II Bortezomib Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens Terminated USA 0
NCT01711528 Phase I Bortezomib + Dexamethasone + Dinaciclib Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Completed USA 0
NCT01723020 Phase I KRT-232 A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma Completed USA 2
NCT01729091 Phase Ib/II Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma Recruiting USA 0
NCT01729338 Phase II Bortezomib + Cyclophosphamide + Lenalidomide Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma Terminated USA 0
NCT01734928 Phase III Pomalidomide Bortezomib + Dexamethasone Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA | CAN 20
NCT01794507 Phase I Bortezomib + Dexamethasone + Venetoclax A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Completed USA 2
NCT01794520 Phase I Venetoclax Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA 3
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT01827137 Phase I WT1 vaccine Lenalidomide Sargramostim WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated USA 1
NCT01849783 Phase II Bortezomib + Dexamethasone + Melphalan + Thalidomide Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Terminated USA 0
NCT01863550 Phase III Dexamethasone Lenalidomide Carfilzomib Bortezomib Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Active, not recruiting USA 1
NCT01866293 Phase Ib/II Cabozantinib Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma Completed USA 0
NCT01889420 Phase I Dexamethasone + Everolimus + Pomalidomide Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma Terminated USA 0
NCT01919086 Phase II Lenalidomide Bortezomib + Dexamethasone Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Active, not recruiting USA 0
NCT01947140 Phase Ib/II Pralatrexate + Romidepsin Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi) Recruiting USA 0
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT01954784 Phase I Bortezomib + Cyclosporine + Mycophenolate mofetil Lenalidomide Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma Terminated USA 0
NCT01955434 Phase II Cyclophosphamide + LCL161 SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed USA 0
NCT01962792 Phase Ib/II Carfilzomib + Ibrutinib Dexamethasone Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma Completed USA | CAN 0
NCT01965353 Phase I Bortezomib + Dexamethasone + Lenalidomide + Panobinostat A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Completed USA 0
NCT01989598 Phase II Trametinib + Uprosertib Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma Active, not recruiting CAN 0
NCT01995708 Phase I CT7/MAGE-A3/WT1 mRNA-electroporated LCs CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT01997840 Phase Ib/II Dexamethasone + Pomalidomide + Ricolinostat ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Active, not recruiting USA | CAN 2
NCT01998971 Phase I Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma Active, not recruiting USA 2
NCT02030483 Phase I Palbociclib Dexamethasone Lenalidomide Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma Terminated USA 0
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting USA | CAN 12
NCT02036502 Phase I Dexamethasone Lenalidomide + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) Terminated 0
NCT02057640 Phase Ib/II Dexamethasone + Ixazomib + Panobinostat MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma Completed USA 0
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Active, not recruiting USA | CAN 0
NCT02077959 Phase Ib/II Lenalidomide + Pidilizumab Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed USA 0
NCT02086552 Phase II Lenalidomide + Sonidegib Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Active, not recruiting USA 0
NCT02098109 Phase II Plerixafor Filgrastim Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Completed USA 0
NCT02099539 Phase Ib/II ALT-803 A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Unknown status USA 0
NCT02101944 Phase I Carfilzomib + Dexamethasone + Pelareorep Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma Recruiting USA 0
NCT02104427 Phase II Burixafor Filgrastim PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients Completed USA 0
NCT02110563 Phase I DCR-MYC Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Terminated USA 0
NCT02136134 Phase III Daratumumab Bortezomib + Dexamethasone Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA 14
NCT02140840 Phase II Trametinib A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Withdrawn USA 0
NCT02144038 Phase Ib/II Alpelisib + LGH447 LGH447 Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Completed USA 4
NCT02157636 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma Completed 0
NCT02159365 Phase II Dexamethasone + Elotuzumab + Lenalidomide Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Completed USA 0
NCT02186834 Phase Ib/II Dexamethasone + Pegylated liposomal-doxorubicin + Selinexor Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Active, not recruiting USA 0
NCT02188368 Phase II Bortezomib + Carfilzomib + Clarithromycin Pegylated liposomal-doxorubicin + Pomalidomide Pomalidomide Pomalidomide for Lenalidomide for Failures Active, not recruiting USA 0
NCT02189343 Phase I Dexamethasone + Pomalidomide + Ricolinostat Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma Completed USA 0
NCT02192775 Phase II MV-NIS UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus Completed USA 0
NCT02195479 Phase III Bortezomib Daratumumab Melphalan A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Active, not recruiting USA 23
NCT02199665 Phase I Carfilzomib + Dexamethasone + Selinexor Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT02204553 Phase I Bortezomib + Dexamethasone + Panobinostat Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma No longer available USA 0
NCT02211014 Phase I Acalabrutinib Dexamethasone An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma Completed USA 1
NCT02220608 Phase I Bortezomib + Filgrastim Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Completed USA 0
NCT02223598 Phase I CB-5083 CB-5083 + Dexamethasone A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) Terminated USA | CAN 0
NCT02235740 Phase I Carfilzomib Afuresertib + Carfilzomib A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) Terminated USA 0
NCT02252263 Phase I Urelumab Lirilumab Elotuzumab A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma Completed USA 1
NCT02254551 Phase II Bortezomib + Sonidegib Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Terminated USA 0
NCT02283775 Phase I Dexamethasone + Isatuximab + Pomalidomide SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR) Completed USA 0
NCT02289222 Phase Ib/II Dexamethasone + Pembrolizumab + Pomalidomide Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma Terminated USA 0
NCT02291848 Phase I MultiTAA-specific T cells Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM) Active, not recruiting USA 0
NCT02308280 Phase II Bortezomib Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients Active, not recruiting CAN 0
NCT02328014 Phase Ib/II ACP-319 Acalabrutinib ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies Active, not recruiting USA 0
NCT02331368 Phase II Lenalidomide Melphalan Pembrolizumab Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma Completed USA 0
NCT02332850 Phase I Carfilzomib + Isatuximab SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT02334865 Phase I Lenalidomide + Montanide ISA 51 + Sargramostim + SurVaxM SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Recruiting USA 0
NCT02336815 Phase II Dexamethasone + Selinexor Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies Completed USA 5
NCT02343042 Phase Ib/II Bortezomib Dexamethasone + Selinexor Pomalidomide Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma Recruiting USA | CAN 0
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT02367196 Phase I CC-90002 + Rituximab CC-90002 A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers Completed USA 1
NCT02368301 Phase I Dexamethasone + Elotuzumab + Lenalidomide Expanded Access Treatment Protocol CA204-143 Approved for marketing USA 1
NCT02372240 Phase Ib/II Dexamethasone + VLX1570 A Study of VLX1570 and Dexamethasone in Myeloma Patients Terminated USA 0
NCT02375555 Phase II Elotuzumab Bortezomib + Dexamethasone + Lenalidomide Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM Active, not recruiting USA 0
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed USA 0
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting USA 1
NCT02400242 Phase I Citarinostat Dexamethasone Pomalidomide Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma Active, not recruiting USA 4
NCT02401295 Phase I Celecoxib + Itraconazole + Tretinoin ATRA, Celecoxib, and Itraconazole as Maintenance Completed USA 0
NCT02426723 Phase I CWP232291 Dexamethasone + Lenalidomide Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients Completed USA 1
NCT02431208 Phase I Lenalidomide Atezolizumab A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) Completed USA 0
NCT02440464 Phase II Methotrexate + Tacrolimus Ixazomib Fludarabine + Melphalan Bortezomib Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Active, not recruiting USA 0
NCT02441686 Phase II Bortezomib + Dexamethasone + Lenalidomide Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma Active, not recruiting USA 0
NCT02465060 Phase II Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting USA 2
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting USA 0
NCT02504359 Phase I Ixazomib Carmustine + Cytarabine + Etoposide + Melphalan Methotrexate + Tacrolimus Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Completed USA 0
NCT02514382 Phase I Bortezomib + Dexamethasone + Pelareorep Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Unknown status USA 0
NCT02514668 Phase I Isatuximab A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma Active, not recruiting USA 2
NCT02519452 Phase I Daratumumab + rHuPH20 A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA 5
NCT02548962 Phase Ib/II Ibrutinib Dexamethasone + Pomalidomide Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma Terminated USA 5
NCT02568943 Phase I Bortezomib + Dexamethasone + Panobinostat An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma No longer available CAN 5
NCT02569320 Phase I AR-42 + Dexamethasone + Pomalidomide HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma Completed USA 0
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting USA 6
NCT02576977 Phase III Pomalidomide Pembrolizumab Dexamethasone Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Terminated 0
NCT02579824 Phase I Milademetan Tosylate DS-3032b for Relapsed and/or Refractory (RR) Myeloma Terminated USA 0
NCT02579863 Phase III Pembrolizumab Dexamethasone Lenalidomide Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Terminated 0
NCT02603887 Phase I Pembrolizumab Pembrolizumab for Smoldering Multiple Myeloma (SMM) Active, not recruiting USA 0
NCT02605356 Phase Ib/II Radium Ra 223 dichloride Bortezomib Dexamethasone Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma Withdrawn USA | CAN 9
NCT02609230 Phase I ONC201 A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma Completed USA 0
NCT02612779 Phase II Dexamethasone + Elotuzumab + Pomalidomide A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide Completed USA 0
NCT02616640 Phase I Pomalidomide Dexamethasone Durvalumab A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Active, not recruiting USA | CAN 5
NCT02628704 Phase II Carfilzomib + Dexamethasone + Selinexor Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma Withdrawn USA 0
NCT02633059 Phase Ib/II Dexamethasone + Idasanutlin + Ixazomib Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Active, not recruiting USA 0
NCT02649790 Phase Ib/II KPT-8602 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma Recruiting USA | CAN 0
NCT02654132 Phase II Dexamethasone + Pomalidomide Elotuzumab Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma Active, not recruiting USA | CAN 9
NCT02654990 Phase II Bortezomib + Dexamethasone + Panobinostat Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Active, not recruiting USA | CAN 20
NCT02655458 Phase I Elotuzumab + Lenalidomide Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma Completed USA 0
NCT02658396 Phase I Bortezomib + GO-203-2C GO-203-2C + Bortezomib For Relapsed Or Refractory MM Withdrawn USA 0
NCT02658929 Phase I Idecabtagene Vicleucel Study of bb2121 in Multiple Myeloma Active, not recruiting USA 0
NCT02666209 Phase I Bortezomib + Dexamethasone + Ulocuplumab Dexamethasone + Lenalidomide + Ulocuplumab Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma No longer available USA 0
NCT02675452 Phase I AMG 176 AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia Recruiting USA | CAN 3
NCT02681302 Phase Ib/II Ipilimumab + Nivolumab Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) Active, not recruiting USA 0
NCT02684617 Phase I Dinaciclib + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) Terminated 0
NCT02685826 Phase I Dexamethasone Durvalumab + Lenalidomide A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma Active, not recruiting USA | CAN 6
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting USA 0
NCT02700841 Phase II Melphalan + PVX-410 Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation Recruiting USA 0
NCT02703779 Phase II Bortezomib Filgrastim + Plerixafor Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) Completed USA 0
NCT02716805 Phase I Durvalumab + Tremelimumab Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant Terminated USA 0
NCT02718833 Phase II Bortezomib + Dexamethasone + Elotuzumab + Panobinostat A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma Unknown status USA 0
NCT02719613 Phase II Bortezomib + Dexamethasone + Elotuzumab + Lenalidomide Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab Active, not recruiting USA | CAN 7
NCT02720510 Phase II Panobinostat Bortezomib + Dexamethasone + Lenalidomide A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Terminated USA 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting USA 0
NCT02722941 Phase II Panobinostat Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) Active, not recruiting USA 0
NCT02726581 Phase III Elotuzumab Nivolumab Dexamethasone + Pomalidomide Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma Active, not recruiting USA | CAN 13
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting USA 0
NCT02755597 Phase III Bortezomib + Dexamethasone Bortezomib + Dexamethasone + Venetoclax A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Suspended USA | CAN 14
NCT02757326 Phase Ib/II ABC294640 ABC294640 in Refractory / Relapsed Multiple Myeloma Terminated USA 0
NCT02765854 Phase II Dexamethasone + Ixazomib + Lenalidomide Dexamethasone + Ixazomib Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Recruiting USA 0
NCT02773030 Phase Ib/II Iberdomide Dexamethasone + Iberdomide Daratumumab + Dexamethasone + Iberdomide Bortezomib + Dexamethasone + Iberdomide A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM) Recruiting USA | CAN 7
NCT02780609 Phase Ib/II Dexamethasone + Melphalan + Selinexor Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Active, not recruiting USA 0
NCT02784483 Phase I Atezolizumab Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma Terminated USA 0
NCT02786485 Phase I Rimiducid BPX-501 Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn 0
NCT02802163 Phase Ib/II Carfilzomib + Dexamethasone + Lenalidomide + Panobinostat Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Withdrawn 0
NCT02807454 Phase Ib/II Daratumumab + Dexamethasone + Durvalumab + Pomalidomide Daratumumab + Durvalumab A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003) Active, not recruiting USA | CAN 7
NCT02831686 Phase I Dexamethasone + Ixazomib + Selinexor A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma Completed USA 0
NCT02833610 Phase II Denosumab A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency Recruiting USA 0
NCT02851056 Phase I Ad5-survivin-transduced autologous DC vaccine + Filgrastim + PCV13 vaccine Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) Suspended USA 0
NCT02863991 Phase II ONC201 Oral ONC201 in Relapsed/Refractory Multiple Myeloma Active, not recruiting USA 0
NCT02874742 Phase II Daratumumab Bortezomib + Dexamethasone + Lenalidomide Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Active, not recruiting USA 0
NCT02880228 Phase II Dexamethasone + Lenalidomide + Pembrolizumab Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant Completed USA 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Active, not recruiting USA 0
NCT02891811 Phase II Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Thalidomide Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy Recruiting 2
NCT02899052 Phase II Carfilzomib + Dexamethasone + Venetoclax Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM) Recruiting USA 4
NCT02906332 Phase II Pembrolizumab Dexamethasone Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Active, not recruiting USA 0
NCT02928029 Phase Ib/II Bortezomib + Dexamethasone + Radium Ra 223 dichloride Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma Terminated USA 2
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02943473 Phase II Ibrutinib Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients Terminated USA 0
NCT02948283 Phase 0 Metformin + Ritonavir Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Completed USA 0
NCT02951819 Phase II Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma Completed USA 0
NCT02952573 Phase II Dexamethasone + Erdafitinib Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement Terminated CAN 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting USA 0
NCT02963493 Phase II Dexamethasone + Melflufen A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON) Active, not recruiting USA 3
NCT02978235 Phase Ib/II TAS4464 A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma Terminated USA 0
NCT02990338 Phase III Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Pomalidomide Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM) Active, not recruiting USA | CAN 22
NCT02992483 Phase I MIK665 Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma Completed USA 6
NCT02998047 Phase I Lintuzumab-Ac225 A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Active, not recruiting USA 0
NCT03000452 Phase II Daratumumab + Durvalumab A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005) Completed USA 5
NCT03003728 Phase II ALT-803 + Elotuzumab + Melphalan 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) Withdrawn USA 0
NCT03004287 Phase II Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Active, not recruiting USA 0
NCT03015792 Phase Ib/II Dexamethasone + Ibrutinib + Lenalidomide Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant Suspended USA 0
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA 1
NCT03019666 Phase I Allogeneic NAM NK cells Cyclophosphamide + Fludarabine Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Recruiting USA 0
NCT03030261 Phase II Melphalan Dexamethasone + Elotuzumab + Pomalidomide Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Recruiting USA | CAN 0
NCT03031730 Phase I Carfilzomib + Dexamethasone + KRT-232 + Lenalidomide MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT03068351 Phase I TEN-010 Daratumumab + TEN-010 Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma Completed USA 2
NCT03091257 Phase I Dabrafenib + Trametinib Dabrafenib Trametinib A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting USA 0
NCT03104270 Phase II Carfilzomib + Dexamethasone + Elotuzumab + Pomalidomide Combination Study for High Risk Multiple Myeloma Patients Active, not recruiting USA 0
NCT03106428 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Completed USA 2
NCT03110562 Phase III Bortezomib + Dexamethasone + Selinexor Bortezomib + Dexamethasone Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) Active, not recruiting USA | CAN 19
NCT03110822 Phase I Lenalidomide + Methylprednisolone + Ruxolitinib A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Recruiting USA 0
NCT03111992 Phase I LCL161 + Spartalizumab CJM112 + Spartalizumab Spartalizumab Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma Completed USA 3
NCT03143985 Phase I Pomalidomide + TEW 7197 TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma Recruiting USA 0
NCT03145181 Phase I Teclistamab Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma Recruiting USA 4
NCT03151811 Phase III Dexamethasone + Pomalidomide Dexamethasone + Melflufen A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN) Active, not recruiting USA 20
NCT03168100 Phase II Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Elotuzumab + Lenalidomide 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma Withdrawn USA 0
NCT03168438 Phase II NY-ESO-1-c259T NY-ESO-1-c259T + Pembrolizumab NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma Terminated USA 0
NCT03194867 Phase Ib/II Cemiplimab + Isatuximab Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Active, not recruiting USA | CAN 8
NCT03201250 Phase Ib/II Cabozantinib + Carfilzomib + Dexamethasone Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma Terminated USA 0
NCT03215030 Phase Ib/II Dexamethasone + TAK-573 TAK-573 A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM) Recruiting USA 0
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Recruiting USA 0
NCT03221634 Phase II Daratumumab + Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) Withdrawn USA | CAN 4
NCT03227432 Phase II Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide Elotuzumab + Nivolumab An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma Withdrawn USA 0
NCT03246529 Phase III Filgrastim BKT140 + Filgrastim A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS) Unknown status USA 0
NCT03256045 Phase II Carfilzomib + Dexamethasone + Panobinostat Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Terminated USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Recruiting 4
NCT03266692 Phase I ACTR087 + SEA-BCMA Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma Terminated USA 0
NCT03267888 Phase I Pembrolizumab Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT03269136 Phase I Elranatamab Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma Active, not recruiting USA | CAN 0
NCT03275103 Phase I BFCR4350A Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) Recruiting USA | CAN 2
NCT03275285 Phase III Carfilzomib + Dexamethasone + Isatuximab Carfilzomib + Dexamethasone Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA) Active, not recruiting USA | CAN 14
NCT03287908 Phase I AMG 701 A Phase 1/2 Study of AMG 701 in Subjects With Multiple Myeloma Recruiting USA | CAN 4
NCT03288480 Phase I Imifoplatin A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA 0
NCT03288493 Phase I P-BCMA-101 CAR-T cells P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) Recruiting USA 0
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting CAN 0
NCT03309111 Phase I ISB 1342 Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Recruiting USA 0
NCT03314181 Phase II Bortezomib + Daratumumab + Dexamethasone + Venetoclax Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Venetoclax A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma Recruiting USA | CAN 5
NCT03315026 Phase II Siltuximab Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis Active, not recruiting USA 0
NCT03319667 Phase III Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ) Active, not recruiting USA 20
NCT03333746 Phase II Lenalidomide + Nivolumab Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Terminated USA 0
NCT03338972 Phase I Cyclophosphamide + Fludarabine Anti-BCMA CAR T Cells Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma Active, not recruiting USA 0
NCT03346135 Phase II Melphalan Daratumumab Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma Recruiting USA 0
NCT03357952 Phase I Daratumumab + JNJ-63723283 A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting 3
NCT03361306 Phase II Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M Active, not recruiting USA 0
NCT03361748 Phase II Idecabtagene Vicleucel Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) (bb2121) Active, not recruiting USA | CAN 6
NCT03374085 Phase I CC-92480 + Dexamethasone A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Recruiting USA | CAN 8
NCT03399799 Phase I Talquetamab Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma Recruiting USA 3
NCT03411031 Phase II Elotuzumab + Lenalidomide Dexamethasone Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide Active, not recruiting USA 0
NCT03412565 Phase II Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens Active, not recruiting USA 8
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting USA 0
NCT03428373 Phase II Dexamethasone + Lenalidomide + Rivaroxaban Aspirin + Dexamethasone + Lenalidomide ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy. (RithMM) Unknown status CAN 0
NCT03439280 Phase Ib/II Dexamethasone + Pomalidomide + TAK-079 TAK-079 A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) Active, not recruiting USA 0
NCT03441958 Phase Ib/II Cyclophosphamide + ECT-001 cord blood cells + Fludarabine + Mycophenolate mofetil + Tacrolimus ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma Recruiting CAN 0
NCT03457142 Phase II BMS-188667 + Dexamethasone + Ixazomib Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy Recruiting USA 0
NCT03464916 Phase I CAR2 anti-CD38 A2 CAR T cells Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients Active, not recruiting USA 0
NCT03465540 Phase I AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies Terminated USA 5
NCT03477539 Phase II Daratumumab + Lenalidomide Daratumumab Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma Suspended USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03481556 Phase Ib/II Bortezomib + Dexamethasone + Melflufen Daratumumab + Dexamethasone + Melflufen Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM (ANCHOR) Active, not recruiting USA 3
NCT03486067 Phase I CC-93269 Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma Recruiting USA 4
NCT03489525 Phase I MEDI2228 MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228) Active, not recruiting USA 3
NCT03492138 Phase Ib/II Dexamethasone + Ixazomib + ONC201 Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Terminated USA 0
NCT03502577 Phase I Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine + LY3039478 BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma Suspended USA 0
NCT03503968 Phase Ib/II MDG1011 TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms Recruiting 1
NCT03506360 Phase II Dexamethasone + Ixazomib + Pembrolizumab Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma Active, not recruiting USA 0
NCT03506802 Phase I Filgrastim + Plerixafor Lenalidomide Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Melphalan TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma Withdrawn USA 0
NCT03525678 Phase II belantamab mafodotin-blmf A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody Active, not recruiting USA | CAN 6
NCT03530683 Phase I TTI-622 A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma Recruiting USA 0
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA 1
NCT03539744 Phase III Dexamethasone + Pomalidomide Dexamethasone + Venetoclax A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA) Recruiting USA | CAN 18
NCT03544281 Phase II belantamab mafodotin-blmf + Bortezomib + Dexamethasone belantamab mafodotin-blmf + Dexamethasone + Lenalidomide To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) Recruiting USA | CAN 4
NCT03548207 Phase Ib/II JNJ-68284528 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting USA 1
NCT03567616 Phase II Dexamethasone + Pomalidomide + Venetoclax A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Terminated USA 2
NCT03582033 Phase I SEA-BCMA A Safety Study of SEA-BCMA in Patients With Multiple Myeloma Recruiting USA 0
NCT03589222 Phase II Bortezomib + Daratumumab + Dexamethasone + Selinexor SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma Recruiting 1
NCT03591614 Phase I DKK1 dendritic cell vaccine Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma Not yet recruiting USA 0
NCT03601078 Phase II Idecabtagene Vicleucel An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2) Recruiting USA 5
NCT03602612 Phase I Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma Active, not recruiting USA 0
NCT03605719 Phase I Carfilzomib + Dexamethasone + Nivolumab + Pelareorep Carfilzomib + Dexamethasone + Nivolumab Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT03607643 Phase Ib/II Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Unknown status USA 0
NCT03622775 Phase II Daratumumab Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant Recruiting USA 0
NCT03634800 Phase II Nivolumab Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M) Terminated USA 0
NCT03650491 Phase I FOR46 A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting USA 0
NCT03651128 Phase III Bortezomib + Daratumumab + Dexamethasone Idecabtagene Vicleucel Dexamethasone + Ixazomib + Lenalidomide Daratumumab + Dexamethasone + Pomalidomide Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Recruiting USA | CAN 9
NCT03652064 Phase III Bortezomib + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Active, not recruiting USA | CAN 11
NCT03657420 Phase I Dexamethasone + Nab-Rapamycin + Pomalidomide Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma Withdrawn USA 0
NCT03672318 Phase I ATLCAR.CD138 + Cyclophosphamide + Fludarabine Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT03687125 Phase Ib/II Tinostamustine Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1) Terminated USA 2
NCT03701321 Phase Ib/II Bortezomib + Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone + Venetoclax Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma Withdrawn USA 0
NCT03702725 Phase I Dexamethasone + Ibrutinib + Lenalidomide Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT03710421 Phase I CS1-CAR T cells + Cyclophosphamide + Fludarabine CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma Recruiting USA 0
NCT03713294 Phase II Dexamethasone + Elotuzumab + Pomalidomide Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma Recruiting USA 0
NCT03715478 Phase Ib/II belantamab mafodotin-blmf + Dexamethasone + Pomalidomide Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex Recruiting CAN 0
NCT03729804 Phase III Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA)) Recruiting USA 0
NCT03732703 Phase Ib/II Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) Recruiting USA 0
NCT03741127 Phase I Rimiducid Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Enrolling by invitation USA 0
NCT03742297 Phase III Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide + Melphalan + Prednisone Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years Recruiting 1
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Recruiting 4
NCT03761108 Phase Ib/II REGN5458 First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma Recruiting USA 1
NCT03763162 Phase II Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Ixazomib Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT03770260 Phase I Ixazomib + MLN4924 Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment Suspended USA 0
NCT03773107 Phase Ib/II Carfilzomib + Dexamethasone + Ruxolitinib LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Recruiting USA 0
NCT03782064 Phase II DC myeloma fusion vaccine + Nivolumab Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma Terminated USA 0
NCT03785184 Phase II Dexamethasone + Lenalidomide + Venetoclax A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy Withdrawn USA | CAN 2
NCT03829020 Phase I Metformin + Nelfinavir Bortezomib + Metformin + Nelfinavir Metformin and Nelfinavir in Treating Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting USA 0
NCT03829371 FDA approved Dexamethasone + Lenalidomide Bortezomib + Melphalan + Prednisone STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA Recruiting 1
NCT03837509 Phase Ib/II Daratumumab + INCB001158 Daratumumab INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Terminated USA 2
NCT03841565 Phase II Daratumumab + Dexamethasone + Pomalidomide Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Recruiting USA 0
NCT03848845 Phase II belantamab mafodotin-blmf + Pembrolizumab Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4) Active, not recruiting USA | CAN 2
NCT03896737 Phase II Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone Ixazomib Bortezomib + Dexamethasone + Thalidomide Daratumumab + Ixazomib Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara Recruiting 4
NCT03901963 Phase III Daratumumab + Lenalidomide Lenalidomide A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA) Recruiting USA | CAN 0
NCT03910439 Phase II Avelumab Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma Terminated USA 0
NCT03915184 Phase I Anti-BCMA CAR T Cells Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting USA | CAN 0
NCT03933735 Phase I TNB-383B A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT03937635 Phase III Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma Recruiting USA 0
NCT03942224 Phase II Daratumumab + Dexamethasone + Ixazomib Bortezomib + Daratumumab + Dexamethasone Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) Recruiting USA 0
NCT03948035 Phase III Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM Recruiting 2
NCT03958656 Phase I Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Completed USA 0
NCT03984097 Phase I Dexamethasone + Lenalidomide + TAK-079 Bortezomib + Dexamethasone + Lenalidomide + TAK-079 A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Active, not recruiting USA 0
NCT03989414 Phase Ib/II Bortezomib + CC-92480 + Dexamethasone CC-92480 + Daratumumab + Dexamethasone Carfilzomib + CC-92480 + Dexamethasone A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Recruiting USA | CAN 7
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Recruiting USA 0
NCT04000282 Phase I SAR442085 First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma Recruiting USA 5
NCT04017130 Phase I TAK-169 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting USA 0
NCT04036461 Phase I CC-99712 A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma Recruiting USA | CAN 3
NCT04045028 Phase I MTIG7192A Daratumumab + MTIG7192A MTIG7192A + Rituximab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting USA 1
NCT04045795 Phase I Dexamethasone + Isatuximab + Pomalidomide Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Recruiting USA 5
NCT04052880 Phase II Daratumumab + Ixazomib Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Recruiting USA 0
NCT04071457 Phase III Daratumumab + Lenalidomide + rHuPH20 Lenalidomide S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC) Recruiting USA 0
NCT04083534 Phase I REGN5459 First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM) Recruiting USA 0
NCT04083898 Phase Ib/II Bendamustine + Isatuximab + Prednisone Isatuximab, Bendamustine, and Prednisone in Penta-Refractory Multiple Myeloma Recruiting USA 0
NCT04091126 Phase III Bortezomib + Dexamethasone + Lenalidomide belantamab mafodotin-blmf + Bortezomib + Dexamethasone + Lenalidomide Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma Recruiting USA | CAN 8
NCT04093596 Phase I ALLO-647 + ALLO-715 ALLO-647 + ALLO-715 + Cyclophosphamide + Fludarabine Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL) Active, not recruiting USA 0
NCT04108195 Phase I Daratumumab + Teclistamab Daratumumab + Talquetamab A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma Recruiting USA | CAN 3
NCT04111107 Phase II Precision Medicine for Patients With Identified Actionable Mutations Recruiting USA 0
NCT04119336 Phase II Cyclophosphamide + Dexamethasone + Ixazomib + Nivolumab Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Active, not recruiting USA 0
NCT04123418 Phase I WVT078 A Study of WVT078 in Patients With Multiple Myeloma (MM) Recruiting USA 7
NCT04126200 Phase II belantamab mafodotin-blmf + GSK3359609 belantamab mafodotin-blmf belantamab mafodotin-blmf + GSK3174998 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) Recruiting USA | CAN 7
NCT04133636 Phase II JNJ-68284528 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2) Recruiting USA 7
NCT04136756 Phase I NKTR-255 Daratumumab + NKTR-255 NKTR-255 in Relapsed/Refractory Multiple Myeloma and Non Hodgkin Lymphoma and Combined With Daratumumab for Multiple Myeloma Recruiting USA 0
NCT04140162 Phase II Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy Recruiting USA 0
NCT04142619 Phase I UCARTCS1A Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) Recruiting USA 0
NCT04150692 Phase II Daratumumab Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT04150965 Phase Ib/II Relatlimab BMS-986207 BMS-986207 + Dexamethasone + Pomalidomide Dexamethasone + Pomalidomide + Relatlimab Dexamethasone + Elotuzumab + Pomalidomide Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Recruiting USA 0
NCT04151667 Phase II Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Lenalidomide Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma Recruiting USA 0
NCT04162210 Phase III Dexamethasone + Pomalidomide belantamab mafodotin-blmf Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Recruiting USA | CAN 17
NCT04166565 Phase II Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19) Recruiting 3
NCT04171843 Phase Ib/II Cyclophosphamide + Fludarabine + PBCAR269A Cyclophosphamide + Fludarabine + Nirogacestat + PBCAR269A A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT04176380 Phase II RAPA-201 RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma Recruiting USA 0
NCT04178902 Phase I ABBV-467 A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma Terminated USA 6
NCT04181827 Phase III Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Bortezomib + Cyclophosphamide + Dexamethasone + Fludarabine + JNJ-68284528 + Pomalidomide Cyclophosphamide + Daratumumab + Dexamethasone + Fludarabine + JNJ-68284528 + Pomalidomide A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) Recruiting USA 16
NCT04184050 Phase Ib/II HPN217 A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM Recruiting USA 3
NCT04196491 Phase I Lenalidomide Cyclophosphamide + Fludarabine + Idecabtagene Vicleucel A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) (KarMMa-4) Recruiting USA 0
NCT04205240 Phase II Cyclophosphamide + Daratumumab + Mycophenolate mofetil + Tacrolimus Fludarabine + Melphalan Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Recruiting USA 0
NCT04205409 Phase II Nivolumab Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies Recruiting USA 0
NCT04214093 Phase I AZD0466 A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors Completed USA 0
NCT04244656 Phase I CTX120 A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma Recruiting USA | CAN 2
NCT04246047 Phase III belantamab mafodotin-blmf + Bortezomib + Dexamethasone Bortezomib + Daratumumab + Dexamethasone Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7) Active, not recruiting USA | CAN 18
NCT04258683 Phase II Bortezomib + Cyclophosphamide + Dexamethasone + Pembrolizumab A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE Recruiting CAN 0
NCT04268199 Phase II Bortezomib A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE) Recruiting CAN 0
NCT04268498 Phase II Carfilzomib + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma Recruiting USA 1
NCT04280328 Phase I CPI-444 + Daratumumab CPI-444 Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT04283097 Phase I KPG-818 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Recruiting USA 0
NCT04287855 Phase II Carfilzomib + Isatuximab + Pomalidomide Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma Active, not recruiting 1
NCT04309084 Phase Ib/II CYNK-001 Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Active, not recruiting USA 0
NCT04318327 Phase I PHE885 BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting USA 0
NCT04352205 Phase II Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Thalidomide Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure Recruiting USA 0
NCT04361851 Phase II Daratumumab + Pembrolizumab Study of Dara-Pembro for Multiple Myeloma Patients Recruiting USA 0
NCT04394650 Phase I Cyclophosphamide + Fludarabine CC-98633 A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma Recruiting USA 0
NCT04405167 Phase I Tasquinimod Dexamethasone + Ixazomib + Lenalidomide + Tasquinimod Tasquinimod for the Treatment of Relapsed or Refractory Myeloma Recruiting USA 0
NCT04430894 Phase II Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide Carfilzomib + Isatuximab + Lenalidomide Lenalidomide KRDI in Transplant-Eligible MM Recruiting USA 0
NCT04445701 Phase Ib/II AO-176 AO-176 + Dexamethasone AO-176 + Bortezomib + Dexamethasone Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT04453397 Expanded access TNB-383B Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma No longer available USA 0
NCT04483739 Phase III Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia) Recruiting 7
NCT04484623 Phase III Bortezomib + Dexamethasone + Pomalidomide belantamab mafodotin-blmf + Dexamethasone + Pomalidomide Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8) Recruiting USA 14
NCT04505813 Phase Ib/II NEXI-002 T Cells Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma Recruiting USA 0
NCT04519476 Phase I Lenalidomide + Selinexor Methylprednisolone Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. Recruiting USA 0
NCT04534322 Expanded access Dexamethasone + Melflufen Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma (sEAPort) Approved for marketing USA 0
NCT04543305 Phase I PRT1419 A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Recruiting USA 0
NCT04555551 Phase I MCARH109 MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Recruiting USA 0
NCT04557098 Phase II Teclistamab A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma Recruiting USA | CAN 9
NCT04564703 Phase II Iberdomide Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients Recruiting 4
NCT04566328 Phase III Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial Recruiting USA 0
NCT04570631 Phase I ABBV-621 + Bortezomib + Dexamethasone Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma Recruiting USA 5
NCT04586426 Phase I Talquetamab + Teclistamab A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Recruiting CAN 3
NCT04614636 Phase I Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 FT538 in Subjects With Advanced Hematologic Malignancies Recruiting USA 0
NCT04634552 Phase II Talquetamab A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma Recruiting USA 9
NCT04635735 Phase Ib/II Ipilimumab Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT04643002 Phase Ib/II Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Isatuximab + SAR439459 Isatuximab in Combination With Novel Agents in RRMM Recruiting USA 4
NCT04649060 Phase III Daratumumab + Dexamethasone + Melflufen Daratumumab Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma (LIGHTHOUSE) Active, not recruiting USA 13
NCT04649359 Phase II Elranatamab Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb Recruiting USA | CAN 7
NCT04653246 Phase II Bortezomib + Dexamethasone + Isatuximab + Lenalidomide Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Recruiting USA 0
NCT04661137 Phase II Dexamethasone + Pomalidomide + Selinexor Daratumumab + Dexamethasone + Selinexor Carfilzomib + Dexamethasone + Selinexor A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Recruiting USA 0
NCT04674813 Phase I CC-95266 + Cyclophosphamide + Fludarabine A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma Recruiting USA 0
NCT04702425 Phase I MIK665 + VOB560 VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Recruiting 3
NCT04722146 Phase I Nirogacestat + Teclistamab Daratumumab + Pomalidomide + Teclistamab Bortezomib + Daratumumab + Lenalidomide + Teclistamab A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Recruiting USA 4
NCT04751877 Phase III Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide Study of Isatuximab+Lenalidomide+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients (IFM2020-05) Recruiting 1
NCT04756401 Phase II Carfilzomib + Daratumumab + Dexamethasone + Selinexor Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma Not yet recruiting USA 0
NCT04758767 Phase I CID-103 CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma Recruiting 2
NCT04764942 Phase Ib/II Dexamethasone + Pomalidomide + Selinexor Carfilzomib + Dexamethasone + Pomalidomide + Selinexor Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial Recruiting USA 0
NCT04772989 Phase I AB308 + GLS-010 A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies Recruiting USA 0
NCT04775550 Phase II Bortezomib + Daratumumab + Dexamethasone + Lenalidomide DARA RVD For High Risk SMM (PRISM) Recruiting USA 0
NCT04776018 Phase Ib/II TAK-079 + TAK-981 Daratumumab and hyaluronidase-fihj + TAK-981 A Study Of TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT04776395 Phase II Iberdomide Dexamethasone + Iberdomide Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT04782687 Phase II Daratumumab + Dexamethasone + Lenalidomide + Selinexor Phase II Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Recruiting USA 0
NCT04802031 Phase II Isatuximab Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT04802356 Phase II belantamab mafodotin-blmf + Bortezomib + Dexamethasone + Lenalidomide Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Recruiting 1
NCT04824794 Phase Ib/II GEN3014 GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies Recruiting USA 3
NCT04835129 Phase II Dexamethasone + Elotuzumab + Isatuximab + Pomalidomide Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Not yet recruiting USA 0
NCT04843579 Phase II Clarithromycin + Dexamethasone + Pomalidomide + Selinexor Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd) Not yet recruiting USA 0
NCT04850599 Phase II Carfilzomib + Isatuximab + Pomalidomide Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma Not yet recruiting USA 0
NCT04855136 Phase Ib/II Iberdomide + Idecabtagene Vicleucel Idecabtagene Vicleucel + LY3039478 Bortezomib + Dexamethasone + Idecabtagene Vicleucel + Pomalidomide Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) Recruiting USA 1
NCT04864522 Phase I SLAMF7 BATs Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (MM BATs) Not yet recruiting USA 0
NCT04879043 Phase Ib/II HDP-101 Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma Not yet recruiting USA 1
NCT04883242 Phase II Carfilzomib + Dexamethasone + Isatuximab + Pomalidomide Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT04891809 Phase II Dexamethasone + Isatuximab + Lenalidomide Dexamethasone + Lenalidomide Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged >=70 Years) With NDMM Not yet recruiting 1
NCT04895410 Phase I TJ011133 Dexamethasone + TJ011133 Daratumumab + Dexamethasone + TJ011133 Carfilzomib + Dexamethasone + TJ011133 Dexamethasone + Pomalidomide + TJ011133 Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab (TJ011133) With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma Recruiting USA 6
NCT04910568 Phase I BFCR4350A + Tocilizumab A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma Recruiting USA | CAN 1
NCT04912427 Phase I Bortezomib + Dexamethasone + Isatuximab satuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease Not yet recruiting USA 0
NCT04923893 Phase III Dexamethasone + Lenalidomide Cyclophosphamide + Fludarabine + JNJ-68284528 Bortezomib + Dexamethasone + Lenalidomide A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5) Recruiting USA | CAN 23
NCT04925193 Phase II Carfilzomib + Dexamethasone + Selinexor Daratumumab + Dexamethasone + Selinexor Dexamethasone + Pomalidomide + Selinexor Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma Not yet recruiting USA 0
NCT04934475 Phase III Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide Melphalan MInimal Residual Disease Adapted Strategy (MIDAS) Not yet recruiting 1
NCT04942067 Phase Ib/II APG-2575 + Dexamethasone + Lenalidomide APG-2575 + Dexamethasone + Pomalidomide APG-2575 + Daratumumab + Dexamethasone + Lenalidomide APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma Recruiting USA 0
NCT04956302 Phase I Bortezomib + Daratumumab and hyaluronidase-fihj + Dexamethasone + Panobinostat Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Not yet recruiting USA 0
NCT04975555 Phase II Siltuximab Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Not yet recruiting USA 0
NCT04975997 Phase III Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Iberdomide Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM). Not yet recruiting USA | CAN 26
NCT05000450 Phase Ib/II ALLO-605 + ALLO-647 + Cyclophosphamide + Fludarabine Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma Active, not recruiting USA 0
NCT05002816 Phase Ib/II belantamab mafodotin-blmf + Elotuzumab Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma Not yet recruiting USA 0
NCT05005442 Phase II MK-7684A A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) Recruiting USA 3
NCT05028348 Phase III Dexamethasone + Elotuzumab + Pomalidomide Dexamethasone + Pomalidomide + Selinexor A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma Not yet recruiting 6
NCT05032820 Phase II Cyclophosphamide + Fludarabine Idecabtagene Vicleucel + Lenalidomide MM CAR-T to Upgrade Response Not yet recruiting USA 0
NCT05050097 Phase I Lenalidomide + Talquetamab Daratumumab + Lenalidomide + Talquetamab Pomalidomide + Talquetamab Carfilzomib + Talquetamab Carfilzomib + Daratumumab + Talquetamab A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma Not yet recruiting USA 4